Turning Point tracks an impressive ORR rate in NSCLC — but shares skid lower on second look
CHICAGO — Fresh off of a $166 million IPO raise, Turning Point Therapeutics $TPTX joined the opening-day festivities at ASCO with an update on their lead drug repotrectinib — which they plan to pitch for an early approval for ROS1+ advanced non-small cell lung cancer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.